TABLE 1.

Serum HAI antibody titers and GMFRs in response to the A/H1N1, A/H3N2, and B virus strains in all subjects

Strain and treatmentnbGeometric meana HAI titer (95% CI)GMFR (95% CI)
PrevaccinationPostvaccination
A/H1N1
    CAIV-T 107403.86 (2.39, 6.24)6.96 (3.94, 12.30)1.8 (1.19, 2.74)
    CAIV-T <105404.84 (2.85, 8.23)4.84 (2.83, 8.27)1.00 (0.74, 1.35)
    TIV425.56 (3.21, 9.63)13.34 (5.75, 30.95)2.40 (1.62, 3.54)
    Placebo405.10 (3.01, 8.64)5.01 (2.99, 8.39)0.98 (0.68, 1.42)
A/H3N2
    CAIV-T 107404.07 (2.50, 6.63)28.34 (17.03, 47.16)6.96 (3.95, 12.27)
    CAIV-T <105403.93 (2.41, 6.42)4.68 (2.79, 7.83)1.19 (0.88, 1.61)
    TIV424.00 (2.45, 6.52)6.90 (3.90, 12.19)1.72 (1.34, 2.21)
    Placebo403.93 (2.41, 6.40)4.68 (2.76, 7.91)1.19 (0.91, 1.56)
B
    CAIV-T 107405.76 (3.58, 9.27)16.00 (10.51, 24.35)2.78 (1.46, 5.29)
    CAIV-T <105396.28 (4.17, 9.45)c7.72 (4.79, 12.45)1.28 (0.88, 1.88)
    TIV425.38 (3.60, 8.05)10.42 (5.49, 19.76)1.94 (1.25, 3.00)
    Placebo395.51 (3.66, 8.29)7.45 (4.86, 11.43)1.35 (0.82, 2.22)
  • a Geometric mean, antilog of the mean of the log-transformed titer or fold rise.

  • b n, number of subjects in the calculation.

  • c A total of 40 subjects were included for this calculation.